The predictive value of synaptic or neurodegeneration CSF biomarkers for longitudinal change during up to four years of follow-up on the MDRS, CVLT (immediate and delayed recall) and CDR-sb in patients with MCI or AD was examined using linear mixed effect models that included demographics, APOE ε4 and CSF Aβ1-42 and Tau levels (selected relationships are shown in Fig. 3, and all relationships are shown in Table 2) and then added each synaptic marker to this model. Here, MAPT is linked to Alzheimer disease.